Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant–Expressing Melanoma

Abstract excerpt

UNLABELLED: Resistance to RAF inhibitors such as vemurafenib and dabrafenib is a major clinical problem in the treatment of melanoma. Patients with mutant BRAF melanoma that progress on RAF inhibitors have limited treatment options, and drug removal from resistant tumors may elicit multiple effects. A frequent mechanism of resistance to RAF inhibitors is caused by expression of mutant BRAF splice variants. RAF...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cutaneous Melanoma Detection and Management
• Share to Lung Cancer Treatments and Mutations
• Share to Melanoma and MAPK Pathways